ABSTRACT
BACKGROUND: Electrophysiological, imaging, and pathological studies have reported the presence of subtle structural abnormalities in hearts from patients with Brugada syndrome (BrS). However, data concerning disease involvement outside of the right ventricular outflow tract are limited. OBJECTIVES: This study sought to characterize the presence and distribution of ventricular myocardial fibrosis in a cohort of decedents experiencing sudden cardiac death caused by BrS. METHODS: The authors evaluated 28 whole hearts from consecutive sudden cardiac death cases attributed to BrS and 29 hearts from a comparator group comprised of noncardiac deaths (control subjects). Cardiac tissue from 6 regions across the right and left ventricle were stained with Picrosirius red for collagen and tissue composition was determined using image analysis software. Postmortem genetic testing was performed in cases with DNA retained for analysis. RESULTS: Of 28 BrS decedents (75% men; median age of death 25 years), death occurred in sleep or at rest in 24 of 28 (86%). The highest proportion of collagen was observed in the epicardial right ventricular outflow tract of the BrS group (23.7%; 95% CI: 20.8%-26.9%). Ventricular myocardium from BrS decedents demonstrated a higher proportion of collagen compared with control subjects (ratio 1.45; 95% CI: 1.22-1.71; P < 0.001), with no significant interactions with respect to sampling location or tissue layer. There was insufficient evidence to support differences in collagen proportion in SCN5A-positive cases (n = 5) when compared with control subjects (ratio 1.23; 95% CI: 0.75-1.43; P = 0.27). CONCLUSIONS: Brugada syndrome is associated with increased collagen content throughout right and left ventricular myocardium, irrespective of sampling location or myocardial layer.
Subject(s)
Brugada Syndrome/mortality , Death, Sudden, Cardiac , Myocardium/pathology , Adipose Tissue/pathology , Adolescent , Adult , Case-Control Studies , Collagen , Female , Fibrosis , Humans , Image Processing, Computer-Assisted , Male , Middle Aged , Young AdultABSTRACT
Background Optimal management of asymptomatic Brugada syndrome (BrS) with spontaneous type I electrocardiographic pattern is uncertain. Methods and Results We developed an individual-level simulation comprising 2 000 000 average-risk individuals with asymptomatic BrS and spontaneous type I electrocardiographic pattern. We compared (1) observation, (2) electrophysiologic study (EPS)-guided implantable cardioverter-defibrillator (ICD), and (3) upfront ICD, each using either subcutaneous or transvenous ICD, resulting in 6 strategies tested. The primary outcome was quality-adjusted life years (QALYs), with cardiac deaths (arrest or procedural-related) as a secondary outcome. We varied BrS diagnosis age and underlying arrest rate. We assessed cost-effectiveness at $100 000/QALY. Compared with observation, EPS-guided subcutaneous ICD resulted in 0.35 QALY gain/individual and 4130 cardiac deaths avoided/100 000 individuals, and EPS-guided transvenous ICD resulted in 0.26 QALY gain and 3390 cardiac deaths avoided. Compared with observation, upfront ICD reduced cardiac deaths by a greater margin (subcutaneous ICD, 8950; transvenous ICD, 6050), but only subcutaneous ICD improved QALYs (subcutaneous ICD, 0.25 QALY gain; transvenous ICD, 0.01 QALY loss), and complications were higher. ICD-based strategies were more effective at younger ages and higher arrest rates (eg, using subcutaneous devices, upfront ICD was the most effective strategy at ages 20-39.4 years and arrest rates >1.37%/year; EPS-guided ICD was the most effective strategy at ages 39.5-51.3 years and arrest rates 0.47%-1.37%/year, and observation was the most effective strategy at ages >51.3 years and arrest rates <0.47%/year). EPS-guided subcutaneous ICD was cost-effective ($80 508/QALY). Conclusions Device-based approaches (with or without EPS risk stratification) can be more effective than observation among selected patients with asymptomatic BrS. BrS management should be tailored to patient characteristics.
Subject(s)
Brugada Syndrome/therapy , Decision Support Techniques , Defibrillators, Implantable , Electric Countershock/instrumentation , Adult , Asymptomatic Diseases , Brugada Syndrome/diagnosis , Brugada Syndrome/economics , Brugada Syndrome/mortality , Comparative Effectiveness Research , Cost-Benefit Analysis , Defibrillators, Implantable/economics , Electric Countershock/adverse effects , Electric Countershock/economics , Electric Countershock/mortality , Electrocardiography , Health Care Costs , Humans , Middle Aged , Models, Economic , Quality-Adjusted Life Years , Recovery of Function , Time Factors , Treatment OutcomeABSTRACT
OBJECTIVES: Brugada syndrome (BrS) is an ion channelopathy that predisposes affected patients to spontaneous ventricular tachycardia/fibrillation (VT/VF) and sudden cardiac death. The aim of this study is to examine the predictive factors of spontaneous VT/VF. METHODS: This was a territory-wide retrospective cohort study of patients diagnosed with BrS between 1997 and 2019. The primary outcome was spontaneous VT/VF. Cox regression was used to identify significant risk predictors. Non-linear interactions between variables (latent patterns) were extracted using non-negative matrix factorisation (NMF) and used as inputs into the random survival forest (RSF) model. RESULTS: This study included 516 consecutive BrS patients (mean age of initial presentation=50±16 years, male=92%) with a median follow-up of 86 (IQR: 45-118) months. The cohort was divided into subgroups based on initial disease manifestation: asymptomatic (n=314), syncope (n=159) or VT/VF (n=41). Annualised event rates per person-year were 1.70%, 0.05% and 0.01% for the VT/VF, syncope and asymptomatic subgroups, respectively. Multivariate Cox regression analysis revealed initial presentation of VT/VF (HR=24.0, 95% CI=1.21 to 479, p=0.037) and SD of P-wave duration (HR=1.07, 95% CI=1.00 to 1.13, p=0.044) were significant predictors. The NMF-RSF showed the best predictive performance compared with RSF and Cox regression models (precision: 0.87 vs 0.83 vs. 0.76, recall: 0.89 vs. 0.85 vs 0.73, F1-score: 0.88 vs 0.84 vs 0.74). CONCLUSIONS: Clinical history, electrocardiographic markers and investigation results provide important information for risk stratification. Machine learning techniques using NMF and RSF significantly improves overall risk stratification performance.
Subject(s)
Algorithms , Brugada Syndrome/mortality , Death, Sudden, Cardiac/epidemiology , Electrocardiography , Risk Assessment/methods , Brugada Syndrome/complications , Brugada Syndrome/diagnosis , Cohort Studies , Death, Sudden, Cardiac/etiology , Female , Hong Kong/epidemiology , Humans , Male , Middle Aged , Retrospective Studies , Survival Rate/trendsABSTRACT
BACKGROUND: The recently recommended single lead-based criterion for the diagnosis of Brugada syndrome may lead to overdiagnosis of this disorder and overestimation of the risk of sudden cardiac death. AIM: To investigate the value of a single-lead diagnosis in patients with Brugada syndrome and a spontaneous type 1 electrocardiogram. METHODS: Consecutive patients with Brugada syndrome were included in a multicentre prospective registry; only those with a spontaneous type 1 electrocardiogram were enrolled. Clinical and electrocardiogram data were reviewed by two physicians blinded to the patients' clinical and genetic status. RESULTS: Among 1613 patients, 505 (31%) were enrolled (79% male; mean age 46±15 years). A spontaneous type 1 electrocardiogram pattern was found in one lead in 250 patients (group 1), in two leads in 227 patients (group 2) and in three leads in 27 patients (group 3). Groups were similar except for individuals in group 3, who presented more frequently a fragmented QRS complex, an early repolarization pattern and a prolonged Tpeak-Tend interval. After a mean follow-up of 6.4±4.7 years, ventricular arrhythmia, sudden cardiac death or implantable cardiac defibrillator shock occurred in 46 (9%) patients, without differences between groups. CONCLUSION: The prognosis of Brugada syndrome with a spontaneous type 1 electrocardiogram pattern does not appear to be affected by the number of leads required for the diagnosis.
Subject(s)
Brugada Syndrome/diagnosis , Electrocardiography/instrumentation , Heart Rate , Action Potentials , Adult , Aged , Brugada Syndrome/mortality , Brugada Syndrome/physiopathology , Brugada Syndrome/therapy , Death, Sudden, Cardiac/epidemiology , Death, Sudden, Cardiac/prevention & control , Defibrillators, Implantable , Electric Countershock/instrumentation , Female , France , Heart Rate/genetics , Humans , Male , Middle Aged , Mutation , NAV1.5 Voltage-Gated Sodium Channel/genetics , Predictive Value of Tests , Prognosis , Prospective Studies , Registries , Reproducibility of Results , Risk Factors , Time FactorsABSTRACT
OBJECTIVE: Sudden cardiac death (SCD) in families with premature atherosclerosis (PAS) is generally attributed to lethal arrhythmias during myocardial infarction. Yet, such arrhythmias may also arise from non-ischaemic inherited susceptibility. We aimed to test the hypothesis that Brugada syndrome is prevalent among families with PAS in which SCD occurred. METHODS: We investigated all patients who underwent Ajmaline testing to screen them for Brugada syndrome because of unexplained familial SCD in the Amsterdam University Medical Centers between 2004 and 2017. We divided the cohort into two groups based on a positive family history for PAS. All individuals with a positive Ajmaline test were screened for SCN5A-mutation. RESULTS: In families with SCD and PAS, the prevalence of positive Ajmaline test was similar to families with SCD alone (22% vs 19%). The number of SCD cases in families with SCD and PAS was higher (2.34 vs 1.63, p<0.001) and SCD occurred at older age in families with SCD and PAS (42 years vs 36 years, p<0.001), while the prevalence of SCN5A mutations was lower (3% vs 18%, p<0.05). CONCLUSIONS: Brugada syndrome has a similar prevalence in families with SCD and PAS as in families with SCD alone, although SCD in families with SCD and PAS occurs in more family members and at older age, while SCN5A mutations in these families are rare. This suggests that the SCD occurring in families with PAS could be related to an underlying genetic predisposition of arrhythmias, with a different genetic origin. It could be considered to screen families with SCD and PAS for Brugada syndrome.
Subject(s)
Atherosclerosis/mortality , Brugada Syndrome/mortality , Death, Sudden, Cardiac/epidemiology , Adolescent , Adult , Age of Onset , Atherosclerosis/diagnosis , Atherosclerosis/genetics , Brugada Syndrome/diagnosis , Brugada Syndrome/genetics , Child , Female , Genetic Predisposition to Disease , Heredity , Humans , Male , Middle Aged , Mutation , NAV1.5 Voltage-Gated Sodium Channel/genetics , Netherlands , Pedigree , Prevalence , Prognosis , Risk Assessment , Risk Factors , Time Factors , Young AdultABSTRACT
Sudden cardiac death (SCD) secondary to sudden cardiac arrest (SCA) is a leading cause of death in the United States, claiming over a quarter million lives annually, and is directly responsible for 50% of all cardiovascular mortality. Brugada Syndrome (BrS) is an arrhythmogenic cardiovascular channelopathy that predisposes asymptomatic patients who have no identified disease to a high-risk of SCD/SCA as their first cardiac event/disease manifestation. Limited progress has been made in risk prediction of SCA and SCD, with the greatest challenge being the ability to identify the small high-risk subgroups concealed within the larger general population. In conclusion, accurate identification of high-risk asymptomatic BrS patients (through multiparametric risk scores composed of reliable and validated unambiguous clinical variables and biomarkers) may hold utility in improving current SCD prediction algorithms, and the appropriate primary prevention therapy may prove valuable in reducing risk of sudden death for this patient population. This systematic review aims to comprehensively summarize qualitative evidence that explore proposed clinical, electrocardiographic, electrophysiological, and genetic markers for risk stratification of patients with BrS phenotype, and to discuss the best available contemporary evidence regarding therapeutic approach.
Subject(s)
Algorithms , Brugada Syndrome/complications , Death, Sudden, Cardiac/prevention & control , Defibrillators, Implantable , Primary Prevention/methods , Brugada Syndrome/mortality , Cause of Death/trends , Death, Sudden, Cardiac/epidemiology , Death, Sudden, Cardiac/etiology , Electrocardiography , Humans , Incidence , Survival Rate/trends , United States/epidemiologyABSTRACT
Objective: To analyze and summarize the diagnosis and treatment experience of common inherited cardiac arrhythmia syndrome in pediatric patients, and explore the most appropriate therapy. Methods: A retrospective review identified 30 pediatric cases (19 males, 11 females) diagnosed with long QT syndrome (LQTS), Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT), hypertrophic cardiomyopathy (HCM), arrhythmogenc right ventricular cardiomyopathy (ARVC) from January 2008 to December 2018 in the Pediatric Cardiology Department, Guangdong Provincial People's Hospital. Data obtained included the diagnosis, treatment and follow-up outcome. Results: The most common inherited cardiac arrhythmia syndromes were LQTS (n=14) including 1 case with epilepsy, CPVT (n=5), HCM (n=7), ARVC (n=1), and BrS (n=3). Twenty-seven cases were admitted to hospital due to syncope, whereas the remaining 3 cases of BrS had not presented with syncope before admission. The average onset age of inherited arrhythmia was (10.0±3.3) years. Genetic testing was performed on 20 patients. The median follow-up time was 40 months. Among 15 patients who underwent implantable cardioverter defibrillator (ICD) and survived, 2 patients had frequent ICD discharge. One patient underwent radiofrequency ablation, and the other one received left cardiac sympathetic denervation and an increased ICD defibrillation threshold, and the number of ICD discharge was significantly reduced. Among 10 patients who received drug therapy, 4 patients including two patients who discontinued treatment without advices died. Two patients whose parents refused treatment died, 1 case diagnosed with unexplained sudden cerebral death, and the remaining 2 cases without indication for drug therapy survived without any treatment. Conclusions: Mortality rate is high in pediatric patients with inherited cardiac arrhythmia and syncope. The therapeutic effect of drugs are not satisfactory, ICD implantation is the most effective treatment to prevent sudden cardiac death currently, but the postoperative frequent discharge should be brought to the forefront and handled in time.
Subject(s)
Arrhythmogenic Right Ventricular Dysplasia/genetics , Brugada Syndrome/genetics , Cardiomyopathy, Hypertrophic/genetics , Long QT Syndrome/genetics , Tachycardia, Ventricular/genetics , Arrhythmias, Cardiac , Arrhythmogenic Right Ventricular Dysplasia/diagnosis , Arrhythmogenic Right Ventricular Dysplasia/mortality , Arrhythmogenic Right Ventricular Dysplasia/therapy , Brugada Syndrome/diagnosis , Brugada Syndrome/mortality , Brugada Syndrome/therapy , Cardiomyopathy, Hypertrophic/diagnosis , Cardiomyopathy, Hypertrophic/mortality , Cardiomyopathy, Hypertrophic/therapy , Child , Death, Sudden, Cardiac , Defibrillators, Implantable , Female , Follow-Up Studies , Genetic Testing , Humans , Long QT Syndrome/diagnosis , Long QT Syndrome/mortality , Long QT Syndrome/therapy , Male , Retrospective Studies , Syncope , Tachycardia, Ventricular/diagnosis , Tachycardia, Ventricular/mortality , Tachycardia, Ventricular/therapy , Treatment OutcomeABSTRACT
BACKGROUND: Brugada syndrome (BrS) is associated with sudden cardiac death (SCD). Although implantable cardioverter-defibrillator (ICD) implantation is recommended, the long-term outcomes and follow-up data with regard to ICD complications have led to controversy. HYPOTHESIS: In the present study, we described the data assimilated in a total of 11 studies, analyzing the outcome in 747 BrS patients receiving ICD. METHODS: Data were performed and analyzed after a systematic review of literature compiled from a thorough database search (PubMed, Web of Science, Cochrane Library, and Cinahl). RESULTS: The mean age of patients receiving ICD was (43.1 ± 13.4, 82.5% males, 46.6% spontaneous BrS type I). Around 15.3% of the patients were admitted due to SCD and 10.4% suffered from atrial arrhythmia. Appropriate shocks were documented in 18.1% of the patients over a mean follow-up period of 82.3 months (47.5-110.4). The following complications were recorded: lead failure and fracture (5.4%), lead perforation (0.7%), lead dislodgement (1.7%), infection (3.9%), pain (0.4%), subclavian vein thrombosis (0.3%), pericardial effusion (0.1%), endocarditis (0.1%), psychiatric problems (1.5%), pneumothorax (0.7%). Inappropriate shocks were documented in 18.1% of the patients. The management of inappropriate shocks was achieved by pulmonary vein isolation (0.5%), drug treatment with sotalol (1.3%) or sotalol with beta-blocker (0.3%) and hydroquinidine (0.1%). CONCLUSIONS: ICD therapy in BrS is associated with relevant ICD-related complications including a substantial risk of inappropriate shocks more frequently in symptomatic BrS patients.
Subject(s)
Brugada Syndrome/therapy , Death, Sudden, Cardiac/prevention & control , Defibrillators, Implantable , Electrocardiography , Brugada Syndrome/complications , Brugada Syndrome/mortality , Death, Sudden, Cardiac/etiology , Follow-Up Studies , Global Health , Humans , Survival Rate/trends , Time FactorsSubject(s)
Brugada Syndrome/pathology , Myocardium/pathology , Action Potentials , Autopsy , Brugada Syndrome/mortality , Brugada Syndrome/physiopathology , Cause of Death , Death, Sudden, Cardiac/epidemiology , Death, Sudden, Cardiac/pathology , Fibrosis , Heart Rate , Humans , Hypertrophy, Left Ventricular/mortality , Hypertrophy, Left Ventricular/pathology , Myocarditis/mortality , Myocarditis/pathology , Myocarditis/virology , Risk Factors , Ventricular RemodelingABSTRACT
Some Brugada syndrome (BrS) patients have been suspected of being in the initial state of arrhythmogenic right ventricular cardiomyopathy (ARVC). This study aimed to clarify the electrocardiographic (ECG) and clinical differences between BrS and ARVC in long-term follow-up (mean 11.9 ± 6.3 years). A total of 50 BrS and 65 ARVC patients with fatal ventricular tachyarrhythmia (VTA) were evaluated according to the revised Task Force Criteria for ARVC. Based on the current diagnostic criteria concerning electrocardiographic, repolarization abnormality was positive in 2.0% and 2.6% of BrS patients at baseline and follow-up, and depolarization abnormality was positive in 6.0% and 12.8% of BrS patients at baseline and follow-up, respectively. At baseline, none of the BrS patients were definitively diagnosed with ARVC. Considering patients' lives since birth, Kaplan-Meier analysis revealed that age at first VTA attack showed the same tendency between the groups (BrS: mean 42.2 ± 12.5 years old vs ARVC: mean 44.8 ± 13.7 years old, log-rank pâ¯=â¯0.123). Moreover, the incidence of VTA recurrence was similar between the groups during follow-up (log-rank pâ¯=â¯0.906). Incidence of sustained monomorphic ventricular tachycardia was significantly higher in ARVC than in BrS whereas the opposite was true for ventricular fibrillation (log-rank p <0.001 and p <0.001, respectively). None of the diagnoses of BrS patients were changed to ARVC during follow-up. During long-term follow-up, although age at first VTA attack and VTA recurrence were similar, BrS consistently exhibited features that differed from those of ARVC.
Subject(s)
Arrhythmogenic Right Ventricular Dysplasia/diagnosis , Brugada Syndrome/diagnosis , Electrocardiography , Tachycardia, Ventricular/diagnosis , Tachycardia, Ventricular/mortality , Adult , Age Factors , Arrhythmogenic Right Ventricular Dysplasia/mortality , Brugada Syndrome/mortality , Cohort Studies , Follow-Up Studies , Humans , Japan , Kaplan-Meier Estimate , Middle Aged , Retrospective Studies , Risk Assessment , Severity of Illness Index , Sex Factors , Survival Analysis , Time FactorsABSTRACT
AIMS: This study was designed to assess the prognostic value of clinical and electrocardiographic parameters in Brugada syndrome (BrS). METHODS AND RESULTS: The study population included 272 consecutive patients (82% males; mean age 43 ± 12 years), with either a spontaneous (n = 137, 50%) or drug-induced (n = 135, 50%) Type 1 Brugada electrocardiogram (ECG) pattern. The study combined endpoint included sudden cardiac death (SCD), cardiac arrest, and appropriate intervention of implantable cardioverter-defibrillator (ICD). A first-degree atrioventricular (AV) block (PR = 219 ± 17 ms) was documented at basal ECG in 45 patients (16.5%); 27 of these underwent an electrophysiological study with recording in 21 (78%) of an HV interval ≥55 ms (mean 61 ± 3 ms). Patients with first-degree AV block had a wider QRS complex (median 110 ms vs. 95 ms; P = 0.04) and more often showed a left anterior hemiblock pattern (n = 13, 29% vs. n = 35, 16%; P = 0.056). During a mean follow-up of 85 ± 55 months, 17 patients (6.3%) experienced ≥1 major arrhythmic events (appropriate ICD intervention, n = 13 and SCD, n = 4). At univariate analysis, the occurrence of major arrhythmic events was significantly associated with a history of syncope or cardiac arrest (P < 0.001), Type 1 ECG pattern (P = 0.04), and first-degree AV block (P < 0.001). Univariate and multivariable predictors of events included a history of syncope or cardiac arrest [hazard ratio (HR) 5.8, 95% confidence interval (95% CI) 2.04-16.5; P < 0.001; and HR 6.68, 95% CI 2.34-19.1; P < 0.001; respectively], a spontaneous Type 1 ECG pattern (HR 1.56, 95% CI 1.03-4.24; P = 0.033; and HR 1.84, 95% CI 1.01-4.29; P = 0.044; respectively) and a first-degree AV block at baseline ECG (HR 3.84, 95% CI 1.47-9.99; P = 0.006; and HR 4.65, 95% CI 2.34-19.1; P = 0.002; respectively). CONCLUSION: Besides a history of cardiac arrest or syncope, first-degree AV block on basal ECG is an independent predictor of malignant arrhythmic events and a stronger marker of arrhythmic risk than a spontaneous 'coved-type' ECG pattern in patients with BrS.
Subject(s)
Atrioventricular Block/diagnosis , Brugada Syndrome/diagnosis , Electrocardiography , Heart Conduction System/physiopathology , Action Potentials , Adult , Atrioventricular Block/mortality , Atrioventricular Block/physiopathology , Atrioventricular Block/therapy , Brugada Syndrome/mortality , Brugada Syndrome/physiopathology , Brugada Syndrome/therapy , Death, Sudden, Cardiac/epidemiology , Defibrillators, Implantable , Electric Countershock/instrumentation , Female , Follow-Up Studies , Heart Arrest/mortality , Heart Arrest/physiopathology , Heart Rate , Humans , Italy/epidemiology , Male , Middle Aged , Predictive Value of Tests , Prognosis , Retrospective Studies , Risk Assessment , Risk Factors , Time FactorsABSTRACT
BACKGROUND: Brugada syndrome (BrS) is a primary arrhythmia syndrome affecting 1 in 2000 of the general population. Genetic testing identifies pathogenic variants in the sodium voltage-gated channel α-subunit 5 gene (SCN5A) in up to 25% of familial BrS. Balanced translocations, which involve the exchange of the ends of 2 different chromosomes, are found in approximately 1 in 500 people. They usually are benign and only rarely are reported to cause arrhythmogenic disorders. OBJECTIVE: The purpose of this study was to identify the genetic mechanism underlying a family with BrS, sick sinus syndrome, cardiac hypertrophy, sudden cardiac death, and multiple miscarriages. METHODS: We clinically evaluated family members with an electrocardiogram, 2-dimensional echocardiogram, and provocation testing with ajmaline challenge. Cytogenetic testing included karyotype and fluorescent in situ hybridization (FISH) analysis. We performed gene panel, exome, and genome sequencing analysis. RESULTS: Sequencing of 128 cardiac genes and exome sequencing of a family with BrS, sick sinus syndrome, cardiac hypertrophy, sudden cardiac death, and multiple miscarriages did not reveal a pathogenic variant. Karyotype and FISH analysis identified a balanced translocation breaking the SCN5A gene on chromosome 3 and the multiple chromosome maintenance 10 gene (MCM10) on chromosome 10 t(3;10)(p22.2;p13). We characterized both translocation breakpoint junctions using genome sequencing and found no regions of sequence homology. CONCLUSION: A balanced translocation breaking SCN5A is a novel mechanism underlying disease in a family with BrS, sick sinus syndrome, cardiac hypertrophy, and sudden cardiac death. Genome sequencing can identify rare chromosomal aberrations causing inherited diseases that may otherwise be missed using gene panel and exome sequencing-based approaches.
Subject(s)
Brugada Syndrome/genetics , Death, Sudden, Cardiac/etiology , Mutation , NAV1.5 Voltage-Gated Sodium Channel/genetics , Translocation, Genetic , Adult , Brugada Syndrome/complications , Brugada Syndrome/mortality , Death, Sudden, Cardiac/epidemiology , Electrocardiography , Female , Genetic Testing , Genotype , Humans , Incidence , Male , Middle Aged , NAV1.5 Voltage-Gated Sodium Channel/metabolism , New South Wales/epidemiology , Pedigree , Survival Rate/trends , Young AdultABSTRACT
PURPOSE: To define the phenotypic and mutational spectrum of epilepsies related to DEPDC5, NPRL2 and NPRL3 genes encoding the GATOR1 complex, a negative regulator of the mTORC1 pathway METHODS: We analyzed clinical and genetic data of 73 novel probands (familial and sporadic) with epilepsy-related variants in GATOR1-encoding genes and proposed new guidelines for clinical interpretation of GATOR1 variants. RESULTS: The GATOR1 seizure phenotype consisted mostly in focal seizures (e.g., hypermotor or frontal lobe seizures in 50%), with a mean age at onset of 4.4 years, often sleep-related and drug-resistant (54%), and associated with focal cortical dysplasia (20%). Infantile spasms were reported in 10% of the probands. Sudden unexpected death in epilepsy (SUDEP) occurred in 10% of the families. Novel classification framework of all 140 epilepsy-related GATOR1 variants (including the variants of this study) revealed that 68% are loss-of-function pathogenic, 14% are likely pathogenic, 15% are variants of uncertain significance and 3% are likely benign. CONCLUSION: Our data emphasize the increasingly important role of GATOR1 genes in the pathogenesis of focal epilepsies (>180 probands to date). The GATOR1 phenotypic spectrum ranges from sporadic early-onset epilepsies with cognitive impairment comorbidities to familial focal epilepsies, and SUDEP.
Subject(s)
Epilepsy/genetics , GTPase-Activating Proteins/genetics , Repressor Proteins/genetics , Tumor Suppressor Proteins/genetics , Adolescent , Brugada Syndrome/genetics , Brugada Syndrome/mortality , Brugada Syndrome/physiopathology , Child , Child, Preschool , DNA Copy Number Variations/genetics , Epilepsy/complications , Epilepsy/epidemiology , Epilepsy/physiopathology , Female , Genetic Predisposition to Disease , Humans , INDEL Mutation/genetics , Infant , Infant, Newborn , Loss of Function Mutation/genetics , Male , Mechanistic Target of Rapamycin Complex 1/genetics , Multiprotein Complexes/genetics , Pedigree , Seizures/complications , Seizures/epidemiology , Seizures/genetics , Seizures/physiopathology , Signal Transduction/geneticsABSTRACT
Inherited conditions that lead to cardiac arrhythmias and sudden cardiac death remain an important cause of morbidity and mortality. Identifying the genes responsible for these rare conditions can provide insights into the more common and heritable forms of sudden cardiac death seen in patients with structural heart disease. We and others have used candidate gene approaches and positional cloning in large families to show that mutations in ion channels and ion channel related proteins cause familial arrhythmia syndromes including long QT and Brugada syndromes. The genes responsible for many familial arrhythmia syndromes and the vast majority of the predisposition to common arrhythmias remain unknown. Using whole exome sequencing in families with Brugada syndrome and idiopathic ventricular fibrillation, we now seek to identify mutations in genes previously not thought to play a significant role in the heart.
Subject(s)
Brugada Syndrome/genetics , DNA Mutational Analysis/methods , Death, Sudden, Cardiac/etiology , Exome Sequencing/methods , Heart Rate/genetics , Mutation , Ventricular Fibrillation/genetics , Brugada Syndrome/complications , Brugada Syndrome/mortality , Brugada Syndrome/physiopathology , Female , Genetic Markers , Genetic Predisposition to Disease , Heredity , Humans , Male , Pedigree , Phenotype , Prognosis , Risk Factors , Ventricular Fibrillation/complications , Ventricular Fibrillation/mortality , Ventricular Fibrillation/physiopathologyABSTRACT
BACKGROUND: Implicit in the genetic evaluation of patients with suspected genetic diseases is the assumption that the genes evaluated are causative for the disease based on robust scientific and statistical evidence. However, in the past 20 years, considerable variability has existed in the study design and quality of evidence supporting reported gene-disease associations, raising concerns of the validity of many published disease-causing genes. Brugada syndrome (BrS) is an arrhythmia syndrome with a risk of sudden death. More than 20 genes have been reported to cause BrS and are assessed routinely on genetic testing panels in the absence of a systematic, evidence-based evaluation of the evidence supporting the causality of these genes. METHODS: We evaluated the clinical validity of genes tested by diagnostic laboratories for BrS by assembling 3 gene curation teams. Using an evidence-based semiquantitative scoring system of genetic and experimental evidence for gene-disease associations, curation teams independently classified genes as demonstrating limited, moderate, strong, or definitive evidence for disease causation in BrS. The classification of curator teams was reviewed by a clinical domain expert panel that could modify the classifications based on their independent review and consensus. RESULTS: Of 21 genes curated for clinical validity, biocurators classified only 1 gene ( SCN5A) as definitive evidence, whereas all other genes were classified as limited evidence. After comprehensive review by the clinical domain Expert panel, all 20 genes classified as limited evidence were reclassified as disputed with regard to any assertions of disease causality for BrS. CONCLUSIONS: Our results contest the clinical validity of all but 1 gene clinically tested and reported to be associated with BrS. These findings warrant a systematic, evidence-based evaluation for reported gene-disease associations before use in patient care.
Subject(s)
Brugada Syndrome/genetics , DNA Mutational Analysis , Death, Sudden, Cardiac/etiology , Mutation , NAV1.5 Voltage-Gated Sodium Channel/genetics , Brugada Syndrome/complications , Brugada Syndrome/diagnosis , Brugada Syndrome/mortality , Genetic Markers , Genetic Predisposition to Disease , Humans , Observer Variation , Phenotype , Predictive Value of Tests , Reproducibility of ResultsABSTRACT
Abstract Background: Brugada syndrome (SBr) is an arrhythmic condition characterized by ST-T segment abnormalities in the right precordial leads associated with a high risk of ventricular arrhythmias and sudden death. Local data regarding the clinical characteristics of patients with a typical electrocardiographic (ECG) pattern undergoing electrophysiological study are scarce. Objective: To evaluate patients with an ECG pattern suggestive of SBr referred for electrophysiological evaluation in a specialized center. Methods: Cohort study of patients referred for electrophysiological study because of an ECG pattern compatible with SBr between January 1998 and March 2017. Results: Of the 5506 procedures, 35 (0.64%) were for SBr investigation, 25 of which (71.42%) were performed in men. The mean age was 43.89 ± 13.1 years. The ECG patterns were as follows: type I, 22 (62.85%); type II, 12 (34.30%); and type III, 1 (2.85%). Twenty-three patients (65.7%) were asymptomatic, 6 (17.14%) had palpitations, 5 (14.3%) had syncope, and 3 (8.6%) had a family history of sudden death. Electrophysiological study induced ventricular tachyarrhythmias in 16 cases (45.7%), the mean ventricular refractory period being 228 ± 36 ms. Ajmaline / procainamide was used in 11 cases (31.4%), changing the ECG pattern to type I in 7 (63.6%). Sixteen cases (45.7%) received an implantable cardioverter defibrillator (ICD). In a mean 5-year follow-up, 1 of the 16 patients (6.25%) with ICD had appropriate therapy for ventricular fibrillation. There was no death. Other arrhythmias occurred in 4 (11.4%) cases. Conclusions: Most patients are men, and a type I ECG pattern is the main indication for electrophysiological study. Class IA drugs have a high ECG conversion rate. The ICD event rate was 6%. (Arq Bras Cardiol. 2018; [online].ahead print, PP.0-0)
Resumo Fundamento: Síndrome de Brugada (SBr) é uma condição arrítmica definida por anormalidades do segmento ST-T em derivações V1-V3 associada a risco elevado de arritmias ventriculares e morte súbita. Dados locais quanto às características clínicas dos pacientes com padrão eletrocardiográfico (ECG) típico avaliados por estudo eletrofisiológico (EEF) são escassos. Objetivo: Avaliar pacientes com padrão ECG sugestivo de SBr encaminhados para EEF em um centro especializado. Métodos: Estudo de coorte de casos encaminhados para EEF por padrão ECG compatível com SBr, entre janeiro de 1998 e março de 2017. Resultados: Dos 5506 procedimentos, 35 (0,64%) foram para investigação de SBr. Vinte e cinco (71,42%) eram homens. Idade média 43,89 ± 13,1 anos. Apresentação ECG foi tipo I em 22 casos (62,85%), tipo II em 12 (34,30%) e tipo III em 1 (2,85%). Vinte e três (65,7%) eram assintomáticos, 6 (17,14%) apresentavam palpitações, 5 (14,3%) síncope, 3 (8,6%) história familiar de morte súbita. Estudo eletrofisiológico induziu taquiarritmias ventriculares em 16 casos (45,7%), sendo o período refratário ventricular médio de 228 ± 36 ms. Utilizou-se ajmalina/procainamida em 11 casos (31,4%), sendo o padrão ECG transformado em tipo I em 7 (63,6%). Dezesseis casos (45,7%) receberam cardiodes fibrilador (CDI). Em seguimento médio de 5 anos, 1 dos 16 pacientes (6,25%) com CDI teve terapia apropriada para fibrilação ventricular. Nenhuma morte foi registrada. Outras arritmias ocorreram em 4 (11,4%) casos. Conclusões: Homens são maioria, sendo o padrão ECG tipo I a principal indicação de EEF. Droga classe IA possui alta taxa de conversão do padrão ECG. A taxa de eventos no CDI foi de 6%. (Arq Bras Cardiol. 2018; [online].ahead print, PP.0-0)
Subject(s)
Humans , Male , Female , Adult , Registries/statistics & numerical data , Defibrillators, Implantable , Brugada Syndrome/surgery , Time Factors , Cohort Studies , Tachycardia, Ventricular/etiology , Electrocardiography , Electrophysiology , Brugada Syndrome/complications , Brugada Syndrome/mortality , Kaplan-Meier EstimateABSTRACT
BACKGROUND: Brugada syndrome (SBr) is an arrhythmic condition characterized by ST-T segment abnormalities in the right precordial leads associated with a high risk of ventricular arrhythmias and sudden death. Local data regarding the clinical characteristics of patients with a typical electrocardiographic (ECG) pattern undergoing electrophysiological study are scarce. OBJECTIVE: To evaluate patients with an ECG pattern suggestive of SBr referred for electrophysiological evaluation in a specialized center. METHODS: Cohort study of patients referred for electrophysiological study because of an ECG pattern compatible with SBr between January 1998 and March 2017. RESULTS: Of the 5506 procedures, 35 (0.64%) were for SBr investigation, 25 of which (71.42%) were performed in men. The mean age was 43.89 ± 13.1 years. The ECG patterns were as follows: type I, 22 (62.85%); type II, 12 (34.30%); and type III, 1 (2.85%). Twenty-three patients (65.7%) were asymptomatic, 6 (17.14%) had palpitations, 5 (14.3%) had syncope, and 3 (8.6%) had a family history of sudden death. Electrophysiological study induced ventricular tachyarrhythmias in 16 cases (45.7%), the mean ventricular refractory period being 228 ± 36 ms. Ajmaline / procainamide was used in 11 cases (31.4%), changing the ECG pattern to type I in 7 (63.6%). Sixteen cases (45.7%) received an implantable cardioverter defibrillator (ICD). In a mean 5-year follow-up, 1 of the 16 patients (6.25%) with ICD had appropriate therapy for ventricular fibrillation. There was no death. Other arrhythmias occurred in 4 (11.4%) cases. CONCLUSIONS: Most patients are men, and a type I ECG pattern is the main indication for electrophysiological study. Class IA drugs have a high ECG conversion rate. The ICD event rate was 6%. (Arq Bras Cardiol. 2018; [online].ahead print, PP.0-0).
Subject(s)
Brugada Syndrome/surgery , Defibrillators, Implantable , Registries/statistics & numerical data , Adult , Brugada Syndrome/complications , Brugada Syndrome/mortality , Cohort Studies , Electrocardiography , Electrophysiology , Female , Humans , Kaplan-Meier Estimate , Male , Tachycardia, Ventricular/etiology , Time FactorsABSTRACT
BACKGROUND: A drug provocation test using a sodium channel blocker (SCB) can unmask a type 1 ECG pattern in patients with Brugada syndrome. However, the prognostic value of the results of an SCB challenge is limited in patients with non-type 1 ECG. We investigated the associations of future risk for ventricular fibrillation with SCB-induced ECG changes and ventricular tachyarrhythmias (VTAs). METHODS AND RESULTS: We administered intravenous pilsicainide to 245 consecutive patients with Brugada syndrome (181 patients with spontaneous type 1 ECG, 64 patients with non-type 1 ECG). ECG parameters before and after the test and occurrence of drug-induced VTAs were evaluated. During a mean follow-up period of 113±57 months, fatal VTA events occurred in 31 patients (sudden death: n=3, ventricular tachycardia/ventricular fibrillation: n=28). Symptomatic patients and spontaneous type 1 ECG were associated with future fatal arrhythmic events. Univariable analysis of ECG parameters after the test showed that long PQ and QRS intervals, high ST level, and SCB-induced VTAs were associated with later VTA events during follow-up. Multivariable analysis showed that symptomatic patients, high ST level (V1) ≥0.3 mV after the test, and SCB-induced VTAs were independent predictors for future fatal arrhythmic events (hazard ratios: 3.28, 2.80, and 3.62, 95% confidence intervals: 1.54-7.47, 1.32-6.35, and 1.64-7.75, respectively; P<0.05). CONCLUSIONS: SCB-induced VTAs and ST-segment augmentation are associated with an increased risk of the development of ventricular tachycardia/ventricular fibrillation events during follow-up in patients with Brugada syndrome.
Subject(s)
Brugada Syndrome/diagnosis , Electrocardiography , Lidocaine/analogs & derivatives , Sodium Channel Blockers/administration & dosage , Administration, Intravenous , Adult , Aged , Brugada Syndrome/complications , Brugada Syndrome/mortality , Brugada Syndrome/physiopathology , Death, Sudden, Cardiac/etiology , Female , Humans , Lidocaine/administration & dosage , Male , Middle Aged , Predictive Value of Tests , Progression-Free Survival , Risk Assessment , Risk Factors , Tachycardia, Ventricular/etiology , Time Factors , Ventricular Fibrillation/etiologySubject(s)
Brugada Syndrome/therapy , Catheter Ablation , Death, Sudden, Cardiac/prevention & control , Ventricular Fibrillation/prevention & control , Anti-Arrhythmia Agents/therapeutic use , Asymptomatic Diseases , Brugada Syndrome/diagnosis , Brugada Syndrome/mortality , Brugada Syndrome/physiopathology , Catheter Ablation/adverse effects , Catheter Ablation/mortality , Clinical Decision-Making , Death, Sudden, Cardiac/epidemiology , Defibrillators, Implantable , Electric Countershock/instrumentation , Electrocardiography , Humans , Patient Selection , Quinidine/therapeutic use , Risk Factors , Treatment Outcome , Ventricular Fibrillation/diagnosis , Ventricular Fibrillation/mortality , Ventricular Fibrillation/physiopathologyABSTRACT
PURPOSE: Brugada syndrome is a hereditary disease linked with an increased risk of sudden death that may require an implantable cardioverter-defibrillator (ICD) in order to halt the arrhythmic events. The aim of this study was to identify possible triggers for appropriate ICD therapies in patients with Brugada syndrome, focusing on their past and current therapeutic profiles. METHODS: Thirty patients with high-risk Brugada syndrome, with ICD implanted at the Coimbra Hospital and University Center, were enrolled. Patients were questioned about their Brugada syndrome history, previous cardiac events, comorbidities, present and past medications, and physical activity. Patients were followed up during 5.8 ± 5.3 years. The ICD was interrogated, and arrhythmic events and device therapies were recorded. The cohort who received appropriate ICD therapies was compared with the remaining patients to determine the potential link between clinical variables and potentially fatal arrhythmic events. RESULTS: More than half of the patients (53.3%) took at least one non-recommended drug, and 16.7% received appropriate ICD therapies, with a long-term rate of 4.0%/year. There was a tendency for more appropriate ICD therapies in patients who took unsafe drugs (85.7 versus 45.5%, p = 0.062), and the mean time between unsafe drug intake and appropriate ICD therapies was 3.8 ± 7.5 days. CONCLUSIONS: This study revealed that the medical community is still unaware of the pharmacological restrictions imposed by Brugada syndrome. Patients who took non-recommended drugs seem to have a higher risk of ventricular arrhythmic events.